Tience® injections for acne scars
The Suitability of Tience® for the Treatment of Acne Scars
We will test whether injections of Tience® can improve moderate to severe acne scars on one side of the face in adults aged 18–40.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Linio Biotech Oy Industry-sponsored |
| Locations | 1 site (Helsinki) |
| Trial ID | NCT07368764 on ClinicalTrials.gov |
What this trial studies
This is an open-label, single-center, split-face, pseudo-randomized trial in which participants receive intradermal Tience® injections to acne-scarred areas on one cheek with the opposite cheek untreated during the comparison period. Treatments are given at Day 0, Day 30, and Day 90, with outcomes tracked for 12 months. Outcome measures include investigator clinical assessments, patient self-evaluation, and VISIA skin analysis to monitor changes in scar severity and overall skin quality. The product is a human-derived, cell-free adipose tissue derivative intended to provide a temporary scaffold to support local cell repopulation and extracellular matrix deposition in damaged skin.
Who should consider this trial
Good fit: Healthy adults aged 18–40 with at least three-year-old acne scars on the cheeks, Fitzpatrick skin types I–III, who are non-smokers and not taking excluded systemic or topical medications are the intended participants.
Not a fit: People with active acne or herpes, darker skin types (Fitzpatrick IV–VI), a tendency for excessive scarring (keloids), autoimmune or clotting disorders, recent use of isotretinoin, or who smoke are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, Tience® injections could reduce scar depth and improve skin texture, offering a minimally invasive option to improve the appearance of long-standing acne scars.
How similar studies have performed: Related approaches using adipose-derived or extracellular matrix products for scar repair have shown some promising but limited results, so this application is relatively novel with preliminary supportive evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: healthy volunteers aged 18-40 years who have at least 3-year- old acne scars on their cheeks. \- Exclusion Criteria: * pregnancy or nursing * cancer or ongoing cancer treatment * an active skin disease * Fitzpatric scale 4-6 skin type * a strong medication used for treating severe acne (e.g., Isotretinoin) * active acne or Herpes * antihistamine medication (if the medication can be paused for 7 days during study visits, participation is possible) * use of biological medications * tendency for excessive scar formation * tendency for urticaria (hives) * systemic medication affecting immunity * autoimmune disease * known disease affecting blood clotting (bleeding or thrombosis tendency) (e.g., von Willebrand disease) * are allergic to the product being studied or any of its ingredients * smoke
Where this trial is running
Helsinki
- Aava Kamppi Medical Centre — Helsinki, Finland (Recruiting)
Study contacts
- Principal investigator: Laura Bouchard, MD, PhD — Aava Kamppi Medical Centre
- Study coordinator: Minna Höst, Coordinator
- Email: minna.host@linio-biotech.com
- Phone: +358407198476
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.